Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-850-2 | CAS number: 133855-98-8 BAS 480 F
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Absorption, excretion and bioavailability
Excretion of 14C-epoxiconazole (BAS 480 F) after oral administration to male and female rats at nominal dose levels of 3 and 100 mg/kg bw was almost complete at 168 h post-dosing, with 90-95% of the administered dose being excreted within 72 h. It occurred mostly via feces (76%-82%) and urine (12%-21%), while in expired air, no significant amounts of radioactivity were detected. Quantitatively, there were no significant differences between sexes, between the low- (ca. 3 mg/kg bw) and high-dose (ca. 100 mg/kg bw) groups, or after repeated oral administration (14x unlabeled and 1x labelled epoxiconazole at the low dose). However, on the whole, excretion occurred later with female animals than with the males. Based on urinary and biliary elimination, oral bioavailability was about 80 % in male and 50 % in female animals.
Pharmacokinetics
Peak plasma concentrations were observed no later than 2 h after administration in both dose groups and with male as well as female animals. Both Cmax and AUCs of the females were about 50% higher at the low, and 10-20% higher at the high-dose, if compared to those of the males. For both sexes, Cmax increased slightly less than proportionally with dose, whereas the AUC was linear over the tested dose range, indicating that the absorption process was not saturated at the high dose level. Terminal half-lives of 5-6 and 32-34 h were observed for the low and high dose, respectively.
Distribution
Epoxiconazole was widely distributed in the organism, with highest residues found in blood, liver, kidneys, spleen, lung, and adrenals. Overall, at 168 h post-dosing, only small amounts of radioactivity were detected in these organs, while only whole blood (but not plasma) and spleen levels were declining more slowly. Taking together the results of both the tissue distribution and pharmacokinetics experiments, it was concluded that epoxiconazole is unlikely to accumulate in tissues.
Metabolism
After oral administration to male and female rats, epoxiconazole was rapidly and intensively metabolized to a large number of biotransformation products. Phase I biotransformation is characterized by the opening of the oxirane ring, hydroxylation of the chlorophenyl ring and also of the fluorinated aromatic ring. In addition, cleavage of the carbon bridge between the two aromatic nuclei is observed. Quantitatively the most important phase II reactions consist of the formation of glutathione adducts and conjugation of glucuronides. Degradation of these glutathione adducts further enlarges the number of metabolites. No major differences were observed with regard to sex and dose level.
Dermal absorption
The dermal absorption of epoxiconazole in vivo was determined by applying test solutions of 1 and 10 g/L, respectively, to the skin of male and female Fisher rats, resulting in applied concentrations of 0.06 and 0.6 mg/cm2 (equivalent to doses of about 3.7 and 37 mg/kg bw). After an exposure duration of 10 h, absorbed amounts were ca. 8% of dose for the lower and ca. 16% of dose for the higher concentration. Dermal penetration through rat skin in vitro was found to be about 2-3 times higher than observed in human skin at 0.0125 and 0.1 mg/cm2, and about 5-7.5 times higher at 0.8 mg/cm2, respectively.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.